Imperial College London
Professor Robert Wilkinson

ProfessorRobertWilkinson

Faculty of Medicine, Department of Infectious Disease

Professor in Infectious Diseases
 
 
 
//

Contact

 

r.j.wilkinson Website

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Au:2021:10.1038/s41591-021-01387-6,
author = {Au, L and Fendler, A and Shepherd, STC and Rzeniewicz, K and Cerrone, M and Byrne, F and Carlyle, E and Edmonds, K and Del, Rosario L and Shon, J and Haynes, WA and Ward, B and Shum, B and Gordon, W and Gerard, CL and Xie, W and Joharatnam-Hogan, N and Young, K and Pickering, L and Furness, AJS and Larkin, J and Harvey, R and Kassiotis, G and Gandhi, S and Swanton, C and Fribbens, C and Wilkinson, KA and Wilkinson, RJ and Lau, DK and Banerjee, S and Starling, N and Chau, I and Turajlic, S},
doi = {10.1038/s41591-021-01387-6},
journal = {Nature Medicine},
pages = {1362--1366},
title = {Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2},
url = {http://dx.doi.org/10.1038/s41591-021-01387-6},
volume = {27},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported with mRNA vaccines and is an extremely rare immune-related adverse event of immune checkpoint inhibitors. We present a case of CRS that occurred 5 d after vaccination with BTN162b2 (tozinameran)—the Pfizer-BioNTech mRNA COVID-19 vaccine—in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy. The CRS was evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-γ/IL-2R/IL-18/IL-16/IL-10) and steroid responsiveness. The close temporal association of vaccination and diagnosis of CRS in this case suggests that CRS was a vaccine-related adverse event; with anti-PD1 blockade as a potential contributor. Overall, further prospective pharmacovigillence data are needed in patients with cancer, but the benefit–risk profile remains strongly in favor of COVID-19 vaccination in this population.
AU  - Au,L
AU  - Fendler,A
AU  - Shepherd,STC
AU  - Rzeniewicz,K
AU  - Cerrone,M
AU  - Byrne,F
AU  - Carlyle,E
AU  - Edmonds,K
AU  - Del,Rosario L
AU  - Shon,J
AU  - Haynes,WA
AU  - Ward,B
AU  - Shum,B
AU  - Gordon,W
AU  - Gerard,CL
AU  - Xie,W
AU  - Joharatnam-Hogan,N
AU  - Young,K
AU  - Pickering,L
AU  - Furness,AJS
AU  - Larkin,J
AU  - Harvey,R
AU  - Kassiotis,G
AU  - Gandhi,S
AU  - Swanton,C
AU  - Fribbens,C
AU  - Wilkinson,KA
AU  - Wilkinson,RJ
AU  - Lau,DK
AU  - Banerjee,S
AU  - Starling,N
AU  - Chau,I
AU  - Turajlic,S
DO  - 10.1038/s41591-021-01387-6
EP  - 1366
PY  - 2021///
SN  - 1078-8956
SP  - 1362
TI  - Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2
T2  - Nature Medicine
UR  - http://dx.doi.org/10.1038/s41591-021-01387-6
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000654957100001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/89741
VL  - 27
ER  -
Download